Brett R. Hagen

CIK: 0001681782

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)11 (84.6%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (15.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KLRS

Kalaris Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (13 total)

KLRS
Kalaris Therapeutics, Inc.
Mar 20, 2026
Sale(S)
Direct
1.9K shares at avg. $6.72$13K
KLRS
Kalaris Therapeutics, Inc.
Mar 19, 2026
Award(A)
Stock Option (Right to Buy)
Direct
60.8K shares-
KLRS
Kalaris Therapeutics, Inc.
Apr 10, 2025
Award(A)
Stock Option (Right to Buy)
Direct
50.3K shares-
KLRS
Kalaris Therapeutics, Inc.
Mar 26, 2025
Sale(S)
Direct
907 shares at avg. $8.97$8K
ALVR
Allovir, Inc.
Feb 21, 2025
Sale(S)
Direct
96 shares at avg. $10.08$967.277
ALVR
Allovir, Inc.
Jan 23, 2025
Sale(S)
Direct
32 shares at avg. $9.45$302.522
ALVR
Allovir, Inc.
Jan 23, 2025
Sale(S)
Direct
4 shares at avg. $9.94$39.761
ALVR
Allovir, Inc.
Jan 10, 2025
Sale(S)
Direct
332 shares at avg. $0.44$146.113
ALVR
Allovir, Inc.
Nov 19, 2024
Sale(S)
Direct
554 shares at avg. $0.55$303.869
ALVR
Allovir, Inc.
Nov 5, 2024
Sale(S)
Direct
1.7K shares at avg. $0.86$1K
ALVR
Allovir, Inc.
Oct 22, 2024
Sale(S)
Direct
486 shares at avg. $0.77$373.151
ALVR
Allovir, Inc.
Oct 21, 2024
Sale(S)
Direct
479 shares at avg. $0.78$373.141
ALVR
Allovir, Inc.
Oct 3, 2024
Sale(S)
Direct
301 shares at avg. $0.81$245.255

		Type	Shares	Price		Ownership
Mar 20, 2026	KLRS Kalaris Therapeutics, Inc.	Sale(S)	1,915	$6.72	$12,869	Direct
Mar 19, 2026	KLRS Kalaris Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	60,800	-	-	Direct
Apr 10, 2025	KLRS Kalaris Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	50,262	-	-	Direct
Mar 26, 2025	KLRS Kalaris Therapeutics, Inc.	Sale(S)	907	$8.97	$8,135	Direct
Feb 21, 2025	ALVR Allovir, Inc.	Sale(S)	96	$10.08	$967	Direct
Jan 23, 2025	ALVR Allovir, Inc.	Sale(S)	32	$9.45	$303	Direct
Jan 23, 2025	ALVR Allovir, Inc.	Sale(S)	4	$9.94	$40	Direct
Jan 10, 2025	ALVR Allovir, Inc.	Sale(S)	332	$0.44	$146	Direct
Nov 19, 2024	ALVR Allovir, Inc.	Sale(S)	554	$0.55	$304	Direct
Nov 5, 2024	ALVR Allovir, Inc.	Sale(S)	1,655	$0.86	$1,431	Direct
Oct 22, 2024	ALVR Allovir, Inc.	Sale(S)	486	$0.77	$373	Direct
Oct 21, 2024	ALVR Allovir, Inc.	Sale(S)	479	$0.78	$373	Direct
Oct 3, 2024	ALVR Allovir, Inc.	Sale(S)	301	$0.81	$245	Direct

1-13 of 13 transactions

About Hagen Brett R

Hagen Brett R (SEC CIK 0001681782) files insider reports with the SEC as Chief Accounting Officer of Kalaris Therapeutics, Inc. (KLRS).

Signal8 holds 10 ownership filings by Hagen Brett R, all Form 4s, filed between Oct 4, 2024 and Mar 23, 2026. Those filings report 13 transactions, from Oct 3, 2024 to Mar 20, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hagen Brett R's filings is in BERKELEY HEIGHTS, NJ.

Recent filings by Hagen Brett R

Mar 20, 2026: Open-market sale of KLRS shares (Form 4, code S).
Mar 19, 2026: Grant or award of KLRS derivative securities (Form 4, code A).
Apr 10, 2025: Grant or award of KLRS derivative securities (Form 4, code A).
Mar 26, 2025: Open-market sale of KLRS shares (Form 4, code S).
Feb 21, 2025: Open-market sale of ALVR shares (Form 4, code S).

Other insiders filing for Kalaris Therapeutics, Inc. (KLRS)

Vandekop Amy O'Leary, VP, Corporate Controller
KEATING LAURIE, Director
Bayko Liisa Ann, Chief Financial Officer
Jovan-Embiricos Morana, Director
Ferrara Napoleone, Director
Hallal David, Director

How to read Form 4 transaction codes